TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07420985: A Multicenter, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of the Investigational Product Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subje

Sponsor: Valenta Pharm JSC · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,115,600

Rescue Site Savings

+$3,381,000

Unlock Full NCT07420985 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07420985 Rescue Dossier →